特奈特普酶
医学
冲程(发动机)
缺血性中风
纤溶剂
心脏病学
内科学
急诊医学
组织纤溶酶原激活剂
溶栓
缺血
心肌梗塞
机械工程
工程类
作者
Lina Palaiodimou,Aristeidis H. Katsanos,Guillaume Turc,Alexandros‐Georgios Asimakopoulos,Dimitris Mavridis,Peter D. Schellinger,Aikaterini Theodorou,Robin Lemmens,Simona Sacco,Apostolos Safouris,M.B. Katan,Amrou Sarraj,Urs Fischer,Georgios Tsivgoulis
出处
期刊:Neurology
[Ovid Technologies (Wolters Kluwer)]
日期:2024-10-16
卷期号:103 (9)
被引量:1
标识
DOI:10.1212/wnl.0000000000209903
摘要
The current European Stroke Organisation expedited recommendation on tenecteplase (TNK) for acute ischemic stroke (AIS) advocates that TNK 0.25 mg/kg can be used alternatively to alteplase (tissue plasminogen activator [TPA]) for AIS of <4.5 hours duration, based on a meta-analytical approach establishing noninferiority. Since the publication of these guidelines, 4 additional randomized controlled clinical trials (RCTs) have provided further insight.
科研通智能强力驱动
Strongly Powered by AbleSci AI